Colorectal Cancer Screening Cohort Study in Shougang Community Population Based on Polygene Methylation Detection Technology
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Colorectal Cancer
- Sponsor
- Singlera Genomics Inc.
- Enrollment
- 18000
- Locations
- 1
- Primary Endpoint
- Sensitivity and specificity of polygene methylation detection in colorectal cancer
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
This study will validate the real world results of polygene methylation detection in colorectal cancer in a large prospective community cohort. In this study, questionnaire survey and polygene methylation detection technology of colorectal cancer were used as preliminary screening methods, and colonoscopy was used as further validation examination method to screen colorectal cancer and precancerous lesions. The diagnosis and outcome of all lesions were based on colonoscopy and pathological examination.
Detailed Description
1. The informed consent signed by shougang Community will be completed in the baseline period: Colorectal cancer risk factors assessment questionnaire, medical history collection, fecal immunochemical (FIT), carcinoembryonic antigen (CEA) blood test and blood bowel cancer gene methylation detection, for colorectal cancer gene methylation detection results more positive subjects and the result of the negative part of the subjects (n = 500), within 3 months after receiving the results complete colonoscopy. 2. Follow-up at 1, 2, 3, 4, and 5 years after baseline included: ① Central follow-up at 1, 3, and 5 years: history collection, colonoscopy, FIT test, and CEA examination; ② Telephone follow-up at the 2nd and 4th years: medical history was collected; (3) Survival outcome registration was performed in the fifth year; Follow-up history was collected at 1, 2, 3, 4, and 5 years after completion of baseline, and survival outcomes were registered at 5 years. 3. During the follow-up, the subjects were confirmed to be diagnosed with colorectal cancer by evaluation (colorectal cancer was diagnosed by colonoscopy), and the subjects who were treated after polyps or adenomas were found during colonoscopy also reached the study endpoint.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Chronological age ≥40 years;
- •Full capacity for action;
- •After enrollment, the participants were able to complete the Colorectal Cancer Risk Factor Assessment Questionnaire and the annual follow-up interviews;
- •In the course of the study, the information related to tumor diagnosis in other hospitals can be timely fed back to the researchers;
Exclusion Criteria
- •History of colorectal cancer and other malignant tumors;
- •Previous colorectal resection;
- •undergoing any cancer-related treatment;
- •Patients who have received major surgical treatment such as blood transfusion or transplantation within 3 months;
- •Participate in other interventional clinical investigators within 3 months;
- •Pregnant or lactating women;
- •Have autoimmune disease, hereditary disease, mental illness/disability, etc
- •Poor compliance, unable to complete the study.
Outcomes
Primary Outcomes
Sensitivity and specificity of polygene methylation detection in colorectal cancer
Time Frame: assessed up to 72 months
To investigate the sensitivity and specificity of polygene methylation in the diagnosis of colorectal cancer in community population, and to evaluate its value as an auxiliary diagnosis
Negative predictive value and positive predictive value of polygene methylation in colorectal cancer
Time Frame: assessed up to 72 months
To obtain the positive predictive value and negative predictive value of polygene methylation test for colorectal cancer early screening, and compare with FIT test and blood CEA test.